Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $2,372,825.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares in the company, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Roivant Sciences Trading Up 0.5 %

Roivant Sciences stock opened at $10.72 on Friday. The firm’s 50 day simple moving average is $11.23 and its 200 day simple moving average is $11.58. The firm has a market capitalization of $7.65 billion, a PE ratio of -71.46 and a beta of 1.25. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on ROIV shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Buy” and a consensus price target of $18.08.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of ROIV. FMR LLC increased its holdings in shares of Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock worth $521,553,000 after buying an additional 2,404,232 shares during the last quarter. State Street Corp increased its holdings in shares of Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Patient Square Capital LP increased its holdings in shares of Roivant Sciences by 2.1% in the 4th quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after buying an additional 251,535 shares during the last quarter. Finally, Two Seas Capital LP increased its holdings in shares of Roivant Sciences by 4.6% in the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock worth $120,285,000 after buying an additional 442,914 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.